Six regulations for the renewal of National Procurement: the same common name can be selected by multiple candidates, and the rising cost allows the price to rise appropriately

On August 31, the industry circulated the "Notice on Doing a Good Job in Continuing Work After the Expiry of the National Organizational Drug Centralized Purchase Agreement (Draft for Solicitation of Comments)", in order to consolidate the results of the national organization's centralized drug procurement reform and realize the procurement agreement After the expiration, the balance continues, and the document puts forward 6 requirements

Mainly involved:

In principle, all nationally sourced varieties should continue to carry out centralized procurement with quantity, and it is not allowed to "negotiate only without quantity"

For the products that were not fully competitive in the previous round, as the number of over-assessed companies increases, the renewal can mainly generate new selected companies and prices through competitive bidding

For the products with sufficient competition in the previous round, it is necessary to comprehensively consider factors such as drug quality, supply capacity, and enterprise credit to produce the selected enterprises

If the price of the last round of centralized procurement was low, and the company is indeed unable to continue to supply at the original selected price due to factors such as rising costs, the selected price may be allowed to rise appropriately

For products with very sufficient competition in the previous round, if there are new products that have been reviewed and the actual sales price of the products in the current market is lower than the price selected in the previous round of centralized procurement, the selected enterprises and the selected prices can be generated through bidding

The same generic name drug can be selected by multiple companies, and the price difference between different selected companies should be appropriately controlled

The full text is as follows:

1.

2.

3.

(2) The varieties with relatively sufficient competition

(3) Varieties that have formed a certain competitive pattern

Fourth, optimize the selection rules

The same generic name drug can be selected by multiple companies, and the price difference between different selected companies should be appropriately controlled

5.
Improving supporting policies

Continue to implement supporting policies such as prepayment of medical insurance funds and coordination of payment standards, and provide medical institutions with incentives for the retention of balances in accordance with relevant regulations
.
With the gradual adjustment of the price of medical services in place, the balance retention ratio can be moderately reduced and maintained at around 20%-30%
.
For areas where there are more patients seeking medical treatment in different places, the proportion of surplus retained for use can be appropriately increased
.

6.
Strengthen performance guarantees

All localities should organize and carry out monitoring of the performance of selected products in centralized procurement, and score and evaluate the supply, quality, and credit of the selected products.
The companies selected in the previous round of centralized procurement have regard to drug quality, production and supply, contract execution, and corporate credit.
If the evaluation result is excellent, the qualification will be given priority under the same conditions; if the evaluation result is general, it can be ranked later in the rules; if the result is poor, the "one-vote veto" can be implemented
.